Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants or their legal representative(s) provided written informed consent prior to undergoing any study-related procedures.~2. Participants were ≥18 years of age at Screening.~3. Participant had pediatric-onset hypophosphatasia (HPP), defined as onset of first sign(s)/symptom (s) of HPP prior to 18 years of age.~4. Participants had a documented diagnosis of HPP as indicated by a documented history of HPP-related skeletal abnormalities and 1 or more of the following:~   * Documented tissue-nonspecific alkaline phosphatase (TNSALP) gene mutation(s) from a certified laboratory.~  * Serum alkaline phosphatase (ALP) level below the age-adjusted normal range AND plasma pyridoxal-5'-phosphate (PLP) above the upper limit of normal at Screening.~5. Participants had a plasma inorganic pyrophosphate (PPi) level of ≥3.9 micromolar (µM) at Screening.~6. Female participants of childbearing potential had a negative pregnancy test at the time of enrollment.~7. Sexually active male and female participants of childbearing potential agreed to use a highly effective method of birth control during the study.~8. Female participants not of child-bearing potential due to sterilization (at least 6 weeks after surgical bilateral oophorectomy with or without hysterectomy or at least 6 weeks after tubal ligation) confirmed by medical history, or menopause.~9. Participants were willing to comply with study procedures and the visit schedule.~Exclusion Criteria:~1. Investigational site personnel directly affiliated with this study and/or their immediate families. Immediate family was defined as a spouse, parent, child, or sibling, whether biological or legally adopted.~2. Employees of Alexion Pharmaceuticals.~3. Currently enrolled in a clinical study involving another study drug or non-approved use of a drug or device.~4. Participated, within the last 30 days, in a clinical study involving a study drug (other than the study drug used in this study).~5. Completed or withdrawn from this study or any other study investigating asfotase alfa in the previous 3 years.~6. Women who were pregnant, planning to become pregnant, or breastfeeding.~7. Serum 25-hydroxy Vitamin D levels below 20 nanogram (ng) per milliliter (mL) at Screening.~8. Screening serum creatinine or parathyroid hormone (PTH) levels ≥1.5 times the upper limit of normal.~9. Any medical condition, serious concurrent illness and/or injury, recent orthopedic surgery, or other extenuating circumstance that, in the opinion of the Investigator, may have significantly interfered with study compliance or study endpoints.~10. Prior treatment with bisphosphonates within 2 years of study entry for any length of time or for more than 2 consecutive years at any prior timepoint.~11. Treatment with PTH, strontium, or sclerostin inhibitors within 6 months prior to the first dose of study drug.~12. Unwilling or unable to comply with the use of a data collection device on which study participants directly recorded data.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Asfotase Alfa 0.5 mg/kg Dose (Type: EXPERIMENTAL): Participants received 0.5 milligrams (mg) per kilogram (kg) of asfotase alfa administered subcutaneously (SC) 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
- Asfotase Alfa 2.0 mg/kg Dose (Type: EXPERIMENTAL): Participants received 2.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
- Asfotase Alfa 3.0 mg/kg Dose (Type: EXPERIMENTAL): Participants received 3.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).